Showing 478 news articles about New & experimental hepatitis C treatment

Filters Content type: Editors' picks Topic: New & experimental hepatitis C treatment

News and information about clinical trials and regulatory approval of new medications to treat hepatitis C.

New & experimental hepatitis C treatment

Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily

Editor's pick
Vertex press release
11 November 2012
New & experimental hepatitis C treatment

Boehringer Ingelheim to start late-stage hepatitis C drug trial

Editor's pick
Reuters
11 November 2012
New & experimental hepatitis C treatment

Idenix Reports On IDX719 and IDX184

Editor's pick
Idenix press release
11 November 2012
New & experimental hepatitis C treatment

Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012
New & experimental hepatitis C treatment

Copy of Merck will initiate interferon-free Phase II clinical trials for MK-5172, an investigational, once-daily, oral treatment for chronic hepatitis C virus

Editor's pick
Merck press release
6 November 2012
New & experimental hepatitis C treatment

Avoiding Missteps When Evaluating New HCV Trial Data

Editor's pick
Clinical Care Options (requires registration)
5 November 2012
Pharmaceutical industry

Gilead and the Pharmasset Deal: Do the Ends Justify the Means?

Editor's pick
PropThink
5 November 2012
New & experimental hepatitis C treatment

Vertex Joins Glaxo, J&J in Testing Hepatitis C Combos

Editor's pick
Bloomberg BusinessWeek
1 November 2012
New & experimental hepatitis C treatment

Achillion Pharma Worthy of New Look - TheStreet.com

Editor's pick
Google Alerts - Hepatitis
31 October 2012
New & experimental hepatitis C treatment

BioCryst drops hep C drug on safety issues

Editor's pick
Reuters
31 October 2012
New & experimental hepatitis C treatment

Will Dropping Interferon Be the Magic Bullet for Reducing HCV Mortality?

Editor's pick
Clinical Care Options (requires registration)
26 October 2012
Access to healthcare

Pakistan: PAC forms panel to relaunch cheaper hepatitis medication

Editor's pick
Express Tribune
24 October 2012
New & experimental hepatitis C treatment

Bristol-Myers has brought in Insight Public Affairs - Prepares to launch first hepatitis C drugs in UK

Editor's pick
PR Week
24 October 2012
New & experimental hepatitis C treatment

Setbacks in HCV Drug Development Highlight Uncertainties in Treat or Wait Decisions

Editor's pick
Clinical Care Options (requires registration)
23 October 2012
Pharmaceutical industry

Vertex Draws Collaboration Interest For Hepatitis C Combo

Editor's pick
Bloomberg BusinessWeek
19 October 2012
Pharmaceutical industry

BioCryst scoops up early-stage Hep C drugs in $101M Presidio acquisition

Editor's pick
FierceBiotech
18 October 2012
New & experimental hepatitis C treatment

A New And Interesting Addition To The Hep C Clinical Pipeline

Editor's pick
Seeking Alpha
18 October 2012
New & experimental hepatitis C treatment

MSD bemoans slow uptake for hep C drugs

Editor's pick
Pharma Times
17 October 2012
New & experimental hepatitis C treatment

Abbott's Investigational Interferon-Free Hepatitis C Treatment Regimen Achieved SVR12 (Observed Data) Rates in 99 Percent of Treatment-Naive

Editor's pick
Abbott press release
15 October 2012
New & experimental hepatitis C treatment

HCV Advocates Survey

Editor's pick
Treatment Action Group
15 October 2012
New & experimental hepatitis C treatment

Conference Highlights Report: Therapy of Hepatitis C: Clinical Application and Drug Development

Editor's pick
EASL
2 October 2012
Clinical trials

Ethics of hepatitis C drug pitch questioned

Editor's pick
Boston Globe
25 September 2012
New & experimental hepatitis C treatment

Simeprevir (TMC435) and TMC647055 Interferon Free Combination Hepatitis C Trial Will Commence Shortly

Editor's pick
Medivir press release
21 September 2012
Pharmaceutical industry

Boehringer Ingelheim exits virology research as hep C drugs move down pipeline

Editor's pick
Pharma Times
20 September 2012